Pacific Biosciences Of California (PACB) Depreciation & Amortization (CF) (2010 - 2026)

Pacific Biosciences Of California's Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 57.12% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $10.1 million, a 35.81% decrease from a year earlier, with the FY2025 full-year figure at $13.0 million, down 5.71% from the prior year.
• Depreciation & Amortization (CF) retreated to $2.2 million in Q1 2026 per PACB's latest filing, from $2.7 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $5.1 million in Q1 2025 and bottomed at $2.2 million in Q1 2026.
• The 5-year median for Depreciation & Amortization (CF) is $2.8 million (2023), against an average of $2.9 million.
• Across the five-year window, Depreciation & Amortization (CF) surged 58.36% in 2025 and slumped 57.12% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $2.6 million in 2022, then increased by 17.56% to $3.0 million in 2023, then retreated by 5.68% to $2.8 million in 2024, then retreated by 3.73% to $2.7 million in 2025, then retreated by 19.59% to $2.2 million in 2026.
• Per Business Quant, the three latest PACB Depreciation & Amortization (CF) figures stand at $2.2 million (Q1 2026), $2.7 million (Q4 2025), and $2.5 million (Q3 2025).